{
    "root": "96683b66-279c-4025-982b-5a8e53d5c26e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mekinist",
    "value": "20250307",
    "ingredients": [
        {
            "name": "TRAMETINIB DIMETHYL SULFOXIDE",
            "code": "BSB9VJ5TUT"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLYETHYLENE GLYCOL",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "BETADEX SULFOBUTYL ETHER SODIUM",
            "code": "2PP9364507"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM",
            "code": "GR686LBA74"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "POTASSIUM SORBATE",
            "code": "1VPU26JZZ4"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        },
        {
            "name": "STRAWBERRY",
            "code": "4J2TY8Y81V"
        }
    ],
    "indications": "mekinist kinase inhibitor indicated single agent treatment braf-inhibitor treatment-naïve patients unresectable metastatic melanoma braf v600e v600k mutations detected fda-approved test . ( 1.1 , 2.1 ) mekinist indicated , combination dabrafenib , : treatment patients unresectable metastatic melanoma braf v600e v600k mutations detected fda-approved test . ( 1.1 , 2.1 ) adjuvant treatment patients melanoma braf v600e v600k mutations , detected fda-approved test , involvement lymph node ( ) , following complete resection . ( 1.2 , 2.1 ) treatment patients metastatic non-small cell lung cancer ( nsclc ) braf v600e mutation detected fda-approved test . ( 1.3 , 2.1 ) treatment patients locally advanced metastatic anaplastic thyroid cancer ( atc ) braf v600e mutation , detected fda-approved test , satisfactory locoregional treatment options . ( 1.4 , 2.1 ) treatment adult pediatric patients 1 year age older unresectable metastatic solid tumors braf v600e mutation progressed following prior treatment satisfactory alternative treatment options . indication approved accelerated approval based overall response rate duration response . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) . ( 1.5 , 2.1 ) treatment pediatric patients 1 year age older low-grade glioma ( lgg ) braf v600e mutation require systemic therapy . ( 1.6 , 2.1 ) limitations : mekinist indicated treatment patients colorectal cancer known intrinsic resistance braf inhibition . ( 1.7 , 12.1 )",
    "contraindications": "recommended mekinist adult patients 2 mg orally daily . recommended mekinist pediatric patients based body weight . take mekinist least 1 hour least 2 hours meal . ( 2 )",
    "warningsAndPrecautions": "mekinist tablets : 0.5 mg tablets : yellow , modified oval , biconvex , film-coated tablets ‘ gs ’ debossed one face ‘ tfc ’ opposing face available bottles 30 ( ndc 0078-0666-15 ) . 0.5 mg tablets : yellow , ovaloid , biconvex , unscored film-coated tablets beveled edges novartis logo debossed one side ‘ tt ’ side ; available bottles 30 ( ndc 0078-1105-15 ) . 2 mg tablets : pink , round , biconvex , film-coated tablets ‘ gs ’ debossed one face ‘ hmj ’ opposing face available bottles 30 ( ndc 0078-0668-15 ) . 2 mg tablets : pink , round , biconvex , unscored film-coated tablets beveled edges novartis logo debossed one side ‘ ’ side ; available bottles 30 ( ndc 0078-1112-15 ) . store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . dispense original bottle . remove desiccant . protect moisture light . place medication pill boxes . mekinist oral solution : white almost white powder amber glass bottles , co-packaged press-in bottle adapter oral syringe . bottle contains 4.7 mg trametinib equivalent 5.3 mg trametinib dimethyl sulfoxide . ml reconstituted strawberry flavored trametinib solution contains 0.05 mg trametinib non-solvated parent . ( ndc 0078-1161-47 ) . store refrigerated 2°c 8°c ( 36°f 46°f ) . store original carton protect light moisture . reconstitution , store original bottle 25°c ( 77°f ) freeze . discard unused solution 35 days reconstitution .",
    "adverseReactions": "none .",
    "indications_original": "MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 )",
    "contraindications_original": "The recommended dosage of MEKINIST in adult patients is 2 mg orally once daily. The recommended dosage for MEKINIST in pediatric patients is based on body weight. Take MEKINIST at least 1 hour before or at least 2 hours after a meal. ( 2 )",
    "warningsAndPrecautions_original": "MEKINIST Tablets:\n                  0.5 mg tablets: Yellow, modified oval, biconvex, film-coated tablets with ‘GS’ debossed on one face and ‘TFC’ on the opposing face and are available in bottles of 30 (NDC 0078-0666-15).\n                  0.5 mg tablets: Yellow, ovaloid, biconvex, unscored film-coated tablets with beveled edges and with the Novartis logo debossed on one side and ‘TT’ on the other side; available in bottles of 30 (NDC 0078-1105-15).\n                  2 mg tablets: Pink, round, biconvex, film-coated tablets with ‘GS’ debossed on one face and ‘HMJ’ on the opposing face and are available in bottles of 30 (NDC 0078-0668-15).\n                  2 mg tablets: Pink, round, biconvex, unscored film-coated tablets with beveled edges and with the Novartis logo debossed on one side and ‘LL’ on the other side; available in bottles of 30 (NDC 0078-1112-15).\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Dispense in original bottle. Do not remove desiccant. Protect from moisture and light. Do not place medication in pill boxes.\n                  \n                     MEKINIST for Oral Solution:\n                  White or almost white powder in amber glass bottles, co-packaged with a press-in bottle adapter and an oral syringe. Each bottle contains 4.7 mg of trametinib equivalent to 5.3 mg trametinib dimethyl sulfoxide. Each mL of reconstituted strawberry flavored trametinib solution contains 0.05 mg of trametinib non-solvated parent. (NDC 0078-1161-47).\n                  Store refrigerated at 2°C to 8°C (36°F to 46°F). Store in the original carton to protect from light and moisture.\n                  After reconstitution, store in the original bottle below 25°C (77°F) and do not freeze.\n                  Discard any unused solution 35 days after reconstitution.",
    "adverseReactions_original": "None."
}